• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Masimo beats Street in Q2 as healthcare business catches up

Masimo beats Street in Q2 as healthcare business catches up

August 9, 2022 By Jim Hammerand

Masimo logoMasimo (Nasdaq: MASI) posted second-quarter results today that beat the consensus forecast on Wall Street.

The Irvine, California-based patient monitoring tech company reported profits of $18.1 million, or $0.33 per diluted share, on sales of $565.3 million for the three months ended July 2, 2022, for a bottom-line decrease of 64% and sales growth of 85.3% compared with Q2 2021.

Adjusted to exclude one-time items, earnings per share were $1.35, $0.15 ahead of the Street, where analysts were looking for EPS of $1.20 on sales of $540.6 million.

“Our healthcare business fulfilled most of the delayed shipments from the first quarter by increasing manufacturing output, which boosted our growth in the second quarter. As a result, our healthcare business delivered 11% constant currency revenue growth for the first half of the year,” Masimo CEO and Chair Joe Kiani said in a news release.

Masimo said it expects to log adjusted EPS of $4.34 to $4.57 this year, down from prior guidance of $4.46 to $4.73. The company also decreased its top-line outlook to a range of $1.99 billion to $2.05 billion compared with a range of $2 billion to $2.06 billion previously.

“We are raising our financial guidance on a constant currency basis for fiscal year 2022,” Kiani said. “I’m excited about the expanded potential to address new markets with our recently acquired consumer business, which will advance solutions for our customers at hospitals and at home.”

Marie Thibault and Sam Eiber of BTIG, in a note after Masimo’s earnings call, said the company’s W1 biosensing watch is in limited release and is set to enter a full launch in Q3. There is also an expected 2023 launch of another watch, called Freedom, that is meant to be more consumer-facing. “We continue to expect added investments in product development and marketing will be needed before MASI can report significant revenue contribution from the new consumer health products.”

MASI shares were down slightly in after-hours trading.

Filed Under: Business/Financial News, Digital Health, Featured, MassDevice Earnings Roundup, News Well, Patient Monitoring, Wall Street Beat Tagged With: Masimo

More recent news

  • China reportedly launches country’s first invasive BCI trial
  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe

About Jim Hammerand

Jim Hammerand is the managing editor of Medical Design & Outsourcing. He has more than two decades of journalism experience spanning newspapers, magazines, websites, live events, radio and TV news. For nearly a decade, Hammerand reported and edited business news for American City Business Journals as a reporter and digital editor at the Minneapolis/St. Paul Business Journal and then managing editor of the Puget Sound Business Journal in Seattle. He holds a bachelor’s degree in journalism from the University of Minnesota. He is based near Seattle, Washington, where he and his family live. Connect with him on LinkedIn or by email at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy